Miguel Gil‐Gil

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.3K citations · Full text

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

Robert E. Coleman, David Cameron, David Dodwell et al. · The Lancet Oncology · 2014 · 290 citations

Breast Oncology, Early Breast Cancer, Medicine +9

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer, Amylou C. Dueck, Miguel Martín et al. · The Lancet Oncology · 2021 · 250 citations

Interim Analysis, Endocrine Oncology, Breast Oncology +9

Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial

E. Verger, Miguel Gil‐Gil, Ricardo Yayá et al. · International Journal of Radiation Oncology*Biology*Physics · 2004 · 210 citations

Neuro-oncology, Phase Ii, Radiation Therapy +7

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Aleix Prat, Cristina Saura, Tomás Pascual et al. · The Lancet Oncology · 2019 · 191 citations

Breast Oncology, Medicine, Pharmacology +10